About Natera
Natera news and updates
Natera, Inc. hires Billings
Previously, Dr. Billings has served in Advisor, Director, and Board Chairman roles before leaving to become Chief Medical Officer and Senior Vice President of Medical Affairs at Natera, Inc. "We are elated at the return of Dr. Billings as Chief Executive Officer and Director of Biological Dynamics," said Irwin M. Jacobs, ScD, Board Chairman.
Jan 1, 2022 | benzinga.comNatera, Inc. launched Signatera data from the prospective, multi-center CIRCULATE-Japan trial on Mar 21st 22'.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new Signatera data from the prospective, multi-center CIRCULATE-Japan trial, presented by Dr. Eiji Oki of Kyushu University in an oral presentation at the Society of Surgical Oncology (SSO) 2022 International Conference on Surgical Cancer Care.
Jan 1, 2022 | msoncologysociety.orgCareDx, Inc. filed suit against Natera, Inc. on Apr 10th 19'.
South San Francisco-based CareDx, a precision medicine company serving transplant patients, sued Austin, Texas-based Natera in 2019 for false advertising of its product and likening it to CareDx’s product.
Jan 1, 2020 | medcitynews.comNatera, Inc. recognized as Fast Company's annual list of the World's Most Innovative Companies for 2022
Natera, Inc. (NASDAQ: NTRA ), a global leader in cell-free DNA testing, has been named to Fast Company's annual list of the World's Most Innovative Companies for 2022.
Jan 1, 2022 | prnewswire.comNatera, Inc. hires Tera Eerkes as Vice President of Oncology Product Development
FlemingMartin is pleased to announce that Natera (NASDAQ: NTRA), a global pioneer in genetic testing and diagnostics, has hired Tera Eerkes, Ph.D., as Vice President of Oncology Product Development.
Jan 1, 2022 | flemingmartin.comNatera, Inc. recognized as sixth in the Health category
Natera ranked sixth in the Health category and was recognized for its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its ability to monitor immunotherapy response.
Jan 1, 2022 | biospace.comNatera, Inc. hired Sangeeta Bhorade as M.D., medical director of heart transplantation, and David Ross, M.D., medical director of lung transplantation on Apr 6th 22'.
Sangeeta Bhorade, M.D., appointed as head of organ health medical affairs AUSTIN, Texas, April 6, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the hiring of Sangeeta Bhorade, M.D., as vice president of organ health medical affairs.
Jan 1, 2022 | fox46.comBragar Eagel & Squire PC files suit against Natera, Inc.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) in the United States District Court for the Western District of Texas on behalf of all persons and entities who purchased or otherwise acquired Natera securities between February 26, 2020 and April 19, 2022, both dates inclusive (the “Class Period”).
Jan 1, 2022 | businesswire.comBronstein, Gewirtz & Grossman, LLC files suit against Natera, Inc.
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Natera securities between Febraury 26, 2020, and April 19, 2022, both dates inclusive (the "Class Period").
Jan 1, 2022 | prnewswire.comNatera, Inc. launched RenaCare clinical study on Apr 29th 22'.
Natera this week announced the RenaCare clinical study, aimed at evaluating the clinical utility of the company's Renasight NGS genetic testing panel.
Jan 1, 2022 | 360dx.comGme Law files suit against Natera, Inc.
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) in the United States District Court for the Western District of Texas on behalf of investors who purchased Natera stock between February 26, 2020, and April 19, 2022, inclusive (the “Class Period”).
Jan 1, 2022 | globenewswire.comNatera, Inc. launched RenaCARE (Renasight Clinical Application on Apr 26th 22'.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the RenaCARE (Renasight Clinical Application, Review and Evaluation) study – a real world, prospective, multi-center clinical study to assess the clinical utility of the Renasight™ genetic testing panel.
Jan 1, 2022 | natera.comGlancy Prongay & Murray LLP acquires Natera, Inc.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Natera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA ) common stock between February 26, 2020 and April 19, 2022, inclusive (the “Class Period”).
Jan 1, 2022 | businesswire.comBlock & Leviton LLP files suit against Natera, Inc.
Click Here Now to Get Instant Access to these Trades BOSTON, MASSACHUSETTS / ACCESSWIRE / April 28, 2022 / Block & Leviton announces that a class action lawsuit has been filed against Natera, Inc. for securities law violations.
Jan 1, 2022 | benzinga.comNatera, Inc. had issues with deceptive sales and billing practices on Mar 9th 22'.
Then, on March 9, 2022, Hindenburg Research issued an investigative report alleging, among other things, that "Natera's revenue growth has been fueled by deceptive sales and billing practices aimed at doctors, insurance companies and expectant mothers."
Jan 1, 2020 | lelezard.comNatera, Inc. has issues with violations of the Securities Exchange Act of 1934
The Class : Shareholder rights law firm Robbins LLP informs investors of a class action on behalf of all persons and entities that purchased or otherwise acquired Natera, Inc. (NYSE: NTRA) securities between February 26, 2020 and April 19, 2022, for violations of the Securities Exchange Act of 1934.
Jan 1, 2022 | businesswire.comNatera, Inc. has issues with failing to disclose material information during the Class Period, violating federal securities laws
Natera and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
Jan 1, 2022 | stockhouse.comNatera, Inc. has issues with alleged securities fraud
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Natera investors who were adversely affected by alleged securities fraud.
Jan 1, 2022 | prnewswire.comWolf Haldenstein Adler Freeman & Herz LLP files suit against Natera, Inc.
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Western District of Texas against Natera, Inc. ("Natera") (NASDAQ: NTRA ) on behalf of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive (the "Class Period").
Jan 1, 2022 | prnewswire.comNatera, Inc. has issues with breached their fiduciary duties and violates securities laws
Shareholder rights law firm Robbins LLP is investigating Natera, Inc. (NASDAQ: NTRA) and its officers and directors to determine whether they breached their fiduciary duties and violates securities laws by misrepresenting the reliability and accuracy of the Company's tests and technology.
Jan 1, 2022 | businesswire.comNatera, Inc. hired Liu on Apr 24th 22'.
In her new position as CMO, Dr. Liu will succeed Dr. Alexey Aleshin, who was recently appointed Natera's general manager of early cancer detection.
Jan 1, 2022 | yahoo.comStanford University filed suit against Natera, Inc. on Mar 1st 19'.
The patents are at the center of an infringement suit CareDx and Stanford filed against Natera Inc. and Eurofins Viracor Inc. in March 2019 claiming that Natera's kidney transplant rejection test, described as an "organ transplant rejection assay" and "allograft rejection" test, infringed the three patents.
Jan 1, 2022 | goodwinlaw.comNatera, Inc. launches ESG report
"Natera, Inc. is proud to issue its first ESG report, which includes specific, measurable goals to reinforce its commitment to prioritizing environmental, social and governance initiatives."
Sep 28, 2022 | natera.comNatera, Inc. went public on Nov 16th 22'.
(RTTNews) - Natera, Inc. (NTRA) on Wednesday priced its public offering of 11.43 million shares at $35 per share.
Nov 16, 2022 | businessinsider.comNatera, Inc. launched study in Nature Medicine on Nov 21st 22'.
Natera, Inc. (NASDAQ: NTRA ), a global leader in cell-free DNA testing, today announced the publication of a new study in Nature Medicine, which shows that its mPCR technology is able to assess response to tebentafusp in treatment-refractory metastatic uveal melanoma.
Nov 21, 2022 | streetinsider.comNatera, Inc. received financing of $400M in equity offering on Nov 21st 22'.
Natera ( NASDAQ: NTRA ) is raising $400 million today (November 18, 2022) in a new equity offering.
Nov 21, 2022 | seekingalpha.comNatera, Inc. launched study in JCO Precision Oncology on Dec 9th 22'.
Natera, Inc. (NASDAQ: NTRA ), a global leader in cell-free DNA testing, today announced the publication of a new study in JCO Precision Oncology highlighting the clinical utility of its personalized and tumor-informed molecular residual disease test, Signatera™, for postoperative risk stratification and prediction of recurrence in patients with stage I-III esophageal and gastric cancers (EGCs).
Dec 9, 2022 | prnewswire.comNatera, Inc. launches Prospera Heart dd-cfDNA
Natera launched the Prospera ™ Heart dd-cfDNA test in late 2021.
Dec 20, 2022 | natera.comNatera, Inc. launched liquid biopsy minimal residual disease on Jan 1st 17'.
Natera launched its liquid biopsy minimal residual disease (MRD) test Signatera in 2017.
Dec 21, 2022 | precisiononcologynews.com